1. Metabolic Enzyme/Protease
  2. MMP
  3. Andecaliximab

Andecaliximab  (Synonyms: Anti-MMP9 Reference Antibody (andecaliximab))

Cat. No.: HY-P99351 Purity: ≥95.0%
COA

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

For research use only. We do not sell to patients.

CAS No. : 1518996-49-0

Size Price Stock Quantity
1 mg USD 300 In-stock
5 mg USD 780 In-stock
10 mg USD 1250 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].

Isotype

Human IgG4 kappa

Recommend Isotype Controls
In Vitro

Andecaliximab increases serum IL-7 levels[1].
Andecaliximab (50 μg/mL; 24 h) reduces phosphorylated SMAD2 (pSMAD2) of ABC-like cell lines[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell[1].
Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection; 20 mg/kg, once a week for once
Result: Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Andecaliximab]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG4 kappa
Purity & Documentation

Purity: ≥95.0%

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Andecaliximab
Cat. No.:
HY-P99351
Quantity:
MCE Japan Authorized Agent: